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Accepted 21 October 2014; Published online 6 December 2014AbstractObjectives: To test the hypothesis that the percentage of patients screened that randomize differs between prevention and therapy trials.
Study Design and Setting: Rapid review of randomized controlled trials (RCTs) identified through published systematic reviews in
August 2013. Individually randomized, parallel group controlled RCTs were eligible if they evaluated metformin monotherapy or exercise
for the prevention or treatment of type 2 diabetes. Numbers of patients screened and randomized were extracted by a single reviewer. Per-
centages were calculated for each study for those randomized: as a function of those approached, screened, and eligible. Percentages (95%
confidence intervals) from each individual study were weighted according to the denominator and pooled rates calculated. Statistical het-
erogeneity was assessed using I2.
Results: The percentage of those screened who subsequently randomized was 6.2% (6.0%, 6.4%; 3 studies, I2 5 100.0%) for metfor-
min prevention trials; 50.7% (49.9%, 51.4%; 21 studies, I2 5 99.6%) for metformin treatment trials; 4.8% (4.7%, 4.8%; 14 studies,
I2 5 99.9%) for exercise prevention trials; and 43.3% (42.6%, 43.9%; 28 studies, I2 5 99.8%) for exercise treatment trials.
Conclusion: This study provides qualified support for the hypothesis that prevention trials recruit a smaller proportion of
those screened than treatment trials. Statistical heterogeneity associated with pooled estimates and other study limitations is
discussed.  2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).
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It is well documented that inadequate recruitment poses a
threat to the successful completion of randomized controlled
trials (RCTs) [1]. Excessive optimism about the number of
potentially eligible candidates who are available, or will
need to be approached for screening, is a key contributory
factor; ‘‘Lasagna’s Law’’ [2,3] and ‘‘Muench’s Third
Law’’ [4] state, with tongue partly in cheek, that ‘‘in order
to be realistic, the number of cases promised in any clinical
study must be divided by a factor of at least ten.’’ Some
have proposed a corollary to these lawsdthat the percent
yield of those screened or initially contacted is related toFunding: No specific funding was received for this study.
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licenses/by-nc-nd/3.0/).the restrictiveness of the research protocol’s eligibility
criteria and the motivation of patients to enroll [5,6]. It fol-
lows that when estimating the availability of participants for
a trial, we should apply eligibility criteria carefully to pa-
tient records and make cautious estimates for randomization
rates, based on previous studies that are analogous in terms
of their population, interventions, and research burden [6].
However, the reporting of randomization rates is still
variable, meaning data to guide yield estimates are not al-
ways readily available [7]. In a widely cited reference text,
Spilker and Cramer [5] proposed that we should expect ‘‘1
in 5 [20-27%] screened patients to enroll if the trial offers
benefit for an active medical problem,’’ and, ‘‘1 in 40 [typi-
cally 1-6%]. if the trial offers the possibility of disease
prevention.’’ Their sample was small and unsystematic, be-
ing based on a convenience sample of 10 prevention and 9
treatment trials. A more recent review of 280 highly cited
treatment trials published between 2002 and 2010 reported
a mean nonenrolment rate of 40.1% (standard deviation:ess article under the CC BY-NC-ND license (http://creativecommons.org/
nical Epidemiology 68 (2015) 347e354What is new?
 The percentage of people randomized from those
screened averaged 6% and 5% in prevention
studies compared with 51% and 43% in studies
evaluating the same interventions for treatment.
 Larger prevention studies are unlikely to achieve
randomization rates as high as those that are
typical in treatment trials.
 This should be taken into account when planning
recruitment rates for future randomized controlled
trials.
23.7%) [7]. While encouraging, this proportion may not
generalize to other settings, most notably prevention trials,
which were not represented in the analysis set. Clearly,
there is a need to better establish a realistic recruitment rate
for prevention trials because this has profound implications
for how we design, cost, and manage such work, given the
effort required in screening for eligibility [8,9].
To investigate whether trials investigating disease pre-
vention do indeed recruit smaller percentages of those
screened, we undertook a rapid review of published RCTs
evaluating metformin monotherapy or exercise (alone or
in combination with other lifestyle interventions) for the
prevention or treatment of type 2 diabetes (T2D). We chose
this sample frame because each intervention can be used for
either the prevention or treatment of T2D. We hoped that as
a result, any comparison we made would be controlled for
the comparative appeal to patients of an intervention and
reliably investigate instead the comparative ease of recruit-
ment. As we discuss in the following sections, there are a
number of assumptions in this proposition that may be open
to question.
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2.1. Literature search
Two separate searches were conducted to identify Co-
chrane and other systematic reviews, which had already
selected RCTs evaluating the use of metformin or exercise
for the prevention of, or treatment for, T2D. We used
‘‘search all text’’ operations in the Cochrane Database of
Systematic Reviews with no restrictions on publication
date. The first search was conducted on August 16, 2013,
and used the terms ‘‘diabetes’’ and ‘‘metformin.’’ The sec-
ond was conducted on August 27, 2013, and used the terms
‘‘diabetes’’ and ‘‘exercise.’’ Titles and abstracts were
screened by one researcher. Systematic reviews evaluating
the use of either metformin or exercise, for either the pre-
vention of or treatment for T2D, were included. Thesystematic review articles were obtained, and the trials that
they had deemed eligible for inclusion were compiled so as
to exclude any duplicates. The original research articles
were obtained.
2.2. Study selection
Individually randomized, parallel group controlled trials
were eligible for inclusion if they allocated to one arm
either metformin monotherapy (insulin and additional die-
tary advice permitted) or exercise (including physical activ-
ity, advice on either exercise or physical activity, behavior
change interventions, and supervised exercise). For the
analysis of metformin, we excluded studies where metfor-
min was used in combination with other pharmacother-
apies. For the analysis of exercise, we excluded any study
where the methods described the arms without mention of
exercise. The stated reason for the intervention in any
eligible trial had to be either prevention of diabetes or the
treatment for T2D in adults. Studies that compared metfor-
min monotherapy (as one arm) with exercise (as another
arm) were included. We excluded preventive studies in
which the intervention focused on the prevention of gesta-
tional diabetes and polycystic ovary syndrome (PCOS). We
excluded therapeutic studies which recruited the following
populations: type 1 diabetes, gestational diabetes, PCOS, or
any other population which was not T2D. We excluded pe-
diatric studies. We excluded cluster trials, crossover trials,
and nonrandomized controlled studies. We excluded trials
that were not published in English.
2.3. Data extraction
Each research article was read by the reviewer, and the
data were extracted into a standardized Excel form,
including the details about the population and intervention
studied, whether a CONSORT diagram was published and
the recruitment metrics from the eligibility criteria. The
CONSORT statement proposes that researchers report
how many people were assessed for eligibility and excluded
based on ineligibility or refusal of consent; we recorded
whether these variables were reported.
Where a CONSORT diagram was absent, attempts
were made to extract data from the text. Where data were
absent from the article, but a previous article relating to
the study was cited, this article was retrieved and screened
for data. Where this was not the case, or failed, authors
were contacted to obtain missing data. Where author con-
tact failed, we estimated the absolute numbers from per-
centages, where provided, rounding up to the nearest
whole number.
2.4. Analysis
We defined those ‘‘approached’’ as those invited to
screen or where screening was undertaken based on records,
the number of records to which researchers attempted to
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procedure applied to determine trial eligibility, either
through interaction with an individual (eg, interviews) or
their records (eg, chart reviews). As very few articles con-
tained comprehensive data on how study candidates were
screened, data on the character of screening were not ex-
tracted. We defined ‘‘eligible’’ as satisfying the trial inclu-
sion and exclusion criteria. Crude rates were calculated
for each study for those randomized (numerator) as a func-
tion of those approached, screened, and eligible (denomina-
tors). The overall percentages were derived by calculating
the various rates from each individual study and weighting
them according to the denominator [10]. Pooled rates, with
95% confidence intervals, were then calculated for each
outcome. We used I2 to measure the amount of between-
study variation in conversion (recruitment) rates, which
could not be explained by the play of chance alone (statis-
tical heterogeneity). By convention, I2 values of 25%,
50%, and 75% indicate low, moderate, and high levels of
statistical heterogeneity [11].3. Results
3.1. Systematic reviews
Fig. 1 presents a flow diagram of the study selection pro-
cess. The searches initially identified 220 systematic re-
views related to metformin and 183 related to exercise.
After screening the title, abstract, and keywords for inclu-
sion criteria, we included 10 systematic reviews about the
use of metformin in the prevention (n 5 4 [12e15]) and
treatment (n 5 6 [16e21]) of diabetes. We included 21 sys-
tematic reviews on the use of exercise in the prevention
(n 5 6 [22e27]) and treatment (n 5 15 [28e42]) of dia-
betes. The median date of publication for included system-
atic reviews was 2009 (range 2001e2013).Fig. 1. Study selec3.2. Randomized controlled trials
The systematic reviews contained the following numbers
of unique trials: metformin prevention, n 5 33; metformin
treatment, n 5 107; exercise prevention, n 5 28; and exer-
cise treatment, n 5 146. After data extraction, 6 preventa-
tive and 69 therapeutic RCTs evaluating metformin and 18
preventative and 87 therapeutic RCTs were retrievable,
found to be eligible, and were included in the analysis
(see Supplementary Tables 1e4 for eligible studies and
Tables 5e8 for ineligible studiesdWeb only Appendix at
www.jclinepi.com). There were no duplicate studies (those
which had both exercise and metformin arms) in the anal-
ysis of treatment studies; there were two duplicate studies
in the analysis of prevention studies (The Diabetes Preven-
tion Programme, n 5 3,819 [43,44] and Indian Diabetes
Prevention Programme, n 5 531 [45]). Across the whole
study, 125 unique studies were excluded from the review
because the full article was irretrievable, permanently or
within the timescale of the study (n 5 41); they were inel-
igible study designs (n 5 21); they had the wrong interven-
tion (n5 31); they had the wrong population (n5 30); they
were not published in English (n5 2). The studies included
in the review were published between 1985 and 2011. A
small number of treatment studies were published before
the initial CONSORT statement (1996 [46]dsee Table 1),
and the great majority of the exercise studies were pub-
lished after the first revised statement (2001 [47]).
3.3. Data completion
Table 2 lists the variation in the reporting of recruitment
metrics in the data set. Of the metformin studies, 3 of 6 pre-
vention studies (50%) and 9 of 69 treatment studies (13%)
provided adequate data to determine our primary outcome,
the percentage of those randomized from those screened.
Of the exercise studies, 14 of 18 prevention studies (78%)tion process.
Table 1. Distribution of included studies by date, relative to CONSORT
publications
Study topic
To
1996 1997e2001
2002
onward Earliest Latest
Metformin as
treatment (n 5 69)
14 22 33 1986 2011
Metformin as
prevention (n 5 6)
0 3 3 1998 2005
Exercise as
treatment (n 5 87)
6 8 73 1985 2011
Exercise as
prevention (n 5 18)
0 4 14 1997 2010
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data to determine the percentage of those randomized from
those screened. Of 123 included studies published after
2001, when the revised CONSORT statement was pub-
lished [47], the following numbers reported CONSORT-
required items: flow diagram, 55 (45%); number screened,
60 (49%); number ineligible, 77 (63%); and number with-
holding consent, 46 (37%).
3.4. Conversion rates
Supplementary Tables 1e4 at www.jclinepi.com show
the individual study data which contributed to the meta-
analyses, summarized in Table 3 and Figs. 2e4. The
randomization rate as a percentage of those approached
was 2.6% (2.5%, 2.7%; 2 studies, I2 5 99.3%) for metfor-
min prevention trials; 36.4% (35.0%, 37.9%; 2 studies,
I2 5 99.8%) for metformin treatment trials; 1.9% (1.9%,
2.0%; 8 studies, I2 5 99.8%) for exercise prevention trials;
and 16.4% (16.1%, 16.8%; 10 studies, I2 5 99.3%) for ex-
ercise treatment trials (Fig. 2). The primary outcome,
randomization rate as a percentage of those screened, was
6.2% (6.0%, 6.4%; 3 studies, I2 5 100.0%) for metformin
prevention trials; 50.7% (49.9%, 51.4%; 21 studies,
I2 5 99.6%) for metformin treatment trials; 4.8% (4.7%,
4.8%; 14 studies, I25 99.9%) for exercise prevention trials;
and 43.3% (42.6%, 43.9%; 28 studies, I2 5 99.8%) for ex-
ercise treatment trials (Fig. 3). The randomization rate as a
percentage of those eligible was 48.6% (47.6%, 49.6%; 3
studies, I2 5 98.3%) for metformin prevention trials;
75.6% (74.2%, 76.9%; 9 studies, I2 5 99.8%) for metfor-
min treatment trials; 68.5% (67.9%, 69.1%; 12 studies,Table 2. Completeness of the data set
Presence of.
Metformin
Prevention, % [N [ 6 (3)] Treatment, % [N [
CONSORT diagram 33 (67) 22 (67)
Number approached 33 (67) 3 (9)
Number screeneda 50 (67) 13 (39)
Number eligiblea 50 (67) 32 (97)
Number refused consenta 0 (0) 10 (30)
Number randomizeda 100 (100) 100 (100)
[.] indicates n or % published from 2002.
a Indicates CONSORT recommended metric.I2 5 99.8%) for exercise prevention trials; and 70.4%
(69.7%, 71.2%; 29 studies, I2 5 99.8%) for exercise treat-
ment trials (Fig. 4).4. Discussion
The percentage of people randomized from those
screened averaged 6% and 5% in prevention studies evalu-
ating metformin monotherapy and exercise, respectively,
but 51% and 43% in studies evaluating the same interven-
tions for treatment. There were very high levels of statisti-
cal heterogeneity associated with all pooled estimates, and
this, together with limitations in the review methods and
conduct, implies that findings must be treated cautiously.
Nonetheless, the magnitude of this difference does suggest
that recruitment into trials evaluating preventive and thera-
peutic interventions is different.
This work aimed to test a hypothesis, generated over
twenty years ago, about the relative difficulty of recruiting
to prevention and treatment trials [5]. We felt it was impor-
tant to test this hypothesis as our own experience tells us
that many funders and researchers expect similar randomi-
zation rates across the two study categories. Our work is the
most systematic evaluation of this question of which we are
aware and will raise awareness that researchers should not
typically expect to achieve in prevention studies the high
randomization rates identified as typical by Humphreys
et al. [7] in contemporary treatment trials. Our work also
recognizes some potential sources of variation by evalu-
ating randomization rates for both drug and nondrug inter-
ventions in comparable populations. Future studies should
aim to control for this source of potential variation where
possible. However, our review has a number of limitations.
Rapid reviews aim for explicit and rigorous method but
with concessions on the gold standard systematic review
process, usually necessitated by resource constraints. Such
concessions, such as the use of simpler search strategies
used in our project, are considered legitimate by guidelines,
but other sources of potential bias are more problematic
[48]. For instance, we used a single reviewer to select
and extract data from studies, with recourse to other team
members only when perceived problems arose. Using two
reviewers reduces the possibility that relevant reports are
discarded and results in fewer errors than when selectionExercise
69 (33)] Prevention, % [N [ 18 (14)] Treatment, % [N [ 87 (73)]
50 (57) 26 (31)
39 (43) 11 (15)
78 (86) 33 (45)
67 (71) 33 (45)
17 (21) 16 (22)
100 (100) 100 (100)
Table 3. Summary of conversion rates
Randomized as a percentage of: Prevention Treatment
Those screened (estimate by
Spilker and Cramer [5])
2.5% 20%
This study Metformin Exercise Metformin Exercise
Those approached (%) 2.6 (2.5, 2.7) 1.9 (1.9, 2.0) 36.4 (35.0, 37.9) 16.4 (16.1, 16.8)
Those screened (%) 6.2 (6.0, 6.4) 4.8 (4.7, 4.8) 50.7 (49.9, 51.4) 43.3 (42.6, 43.9)
Those eligible (%) 48.6 (47.6, 49.6) 68.5 (67.9, 69.1) 75.6 (74.2, 76.9) 70.4 (69.7, 71.2)
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[49,50]. By combining the eligible RCTs of several over-
lapping systematic reviews, it is unlikely that we failed to
identify significant numbers of eligible studies. However,
as we have documented, the need to truncate the review
process, together with the inaccessibility of some trial re-
ports, meant that 41 studies were irretrievable by the time
of analysis, introducing unquantifiable bias and undermin-
ing our findings. Most of these reports (33 of 41) related
to the exercise treatment analysis, meaning this aspect of
the study is at greater risk of bias. In addition, where pri-
mary research studies were retrieved and eligible, the qual-
ity of reporting was poor; even trials published after the
revised CONSORT statement of 2001 [47], frequently
omitted recommended items, such as the numbers of study
candidates assessed for eligibility, excluded on eligibility
grounds and refusing consent.
In testing the hypothesis that fewer of those screened
will randomize in prevention studies than in treatment
studies, we have taken a crude approach, categorizing
together studies with often striking methodological differ-
ences. For instance, the presence of an active control is
thought to increase recruitment [51]. The restrictiveness
of an RCT’s eligibility criteria is widely thought to inhibit
accrual as a function of those screened [2,6,8,52]. And, tar-
geted mass mail outs based on database searches are
thought to be a more efficient method of recruitment than
opportunistic approaches during medical consultations for
individually randomized prevention trials in chronic condi-
tions [53]. We did not collect data on any of these or manyFig. 2. Randomization rate as a percentage of those approached.other variables, which might conceivably affect recruitment
rates [52]. Additionally, we have standardized study metrics
in such a way that we could combine trials with a simple,
single-stage screening process with others that have com-
plex multistage processes. It is thought that those with
multistage screening tend to lose larger numbers overall,
with candidates withdrawing between each successive
screen [8]. In our analysis, we have also combined studies
with different pathways to randomization. The basic
assumption is that recruitment happens by approaching
candidates before screening, after which eligibility is estab-
lished: out of choice or necessity, the researchers approach
people first before inviting them for screening, as in The In-
dian Diabetes Prevention Programme [45]. On the other
hand, some studies use routinely collected clinical data to
screen for eligibility before approaching people to consider
study participation, as in the V€asterbotten Intervention Pro-
gramme [54]. Not all those screened as eligible by a study
team using their records, without their direct involvement,
will always be approached. There were no instances in
our sample where researchers reported both numbers ap-
proached and numbers screened and where numbers
screened were larger than numbers approached. Nonethe-
less, the variation in the patient selection pathway is one
likely source of heterogeneity. CONSORT 2010 does not
mandate detailed information about the screening phase
so it is unlikely that reporting of this data will improve in
the near term. This means that published reports may notFig. 3. Randomization rate as a percentage of those screened (primary
outcome). Red vertical lines indicate the percentages expected by
Spilker and Cramer [5] (2.5% and 20%).
Fig. 4. Randomization rate as a percentage of those eligible.
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seeking to improve their reporting should consider the
CONSORT guidance (those screened and numbers ineli-
gible and withholding consent put in the flow diagram) as
a minimum standard for the flow diagram. CONSORT
2010 notes that ‘‘it will sometimes be useful or necessary
to adapt the structure of the flow diagram to a particular
trial’’ [55]. This means researchers may, and we would
encourage them to, describe in detail the methods and re-
sults of multistage screening processes in the flow diagram,
where the information will not contribute to a manuscript’s
word count.
In planning this review, we made certain arbitrary
choices in how to set its scope. It is likely that different
recruitment dynamics may be observed with the use of
different populations (pediatric rather than adult; PCOS
vs. T2D), interventions (combination rather than mono-
therapy), or study designs (crossover or cluster rather than
individually randomized). Perhaps, implicit in the state-
ment by Spilker and Cramer’s [5] aforementioned is the
idea, also expressed by others, that the motivation for
participation in prevention trials is different to that in treat-
ment trials. Spilker and Cramer are not alone in assuming
that participation in treatment trials is often driven by a
desire for symptom relief, whereas if there is any clinical
reward for an essentially healthy person’s participation in
prevention trials, it is comparatively distant in time
[56,57]. This is a rather simplistic view, and the categories
may not always be rigidly distinct. In those studies
included in a systematic review [58] from which adequate
data could be derived, four trials evaluating chemopreven-
tive agents for the prevention of colorectal cancer in high-
risk populations recruited significantly higher percentages
(median 71%; range 65% to 89%) of those screened than
eight trials in the general population (median 13%; range
2% to 61%) [59]. Although this reflects a range of factors,
it might indicate that the perceived risk of a hazard
emerging in the future increases the chances of an individ-
ual recruiting to a prevention trial. Our prevention studiesfocus on prediabetes, a population which is arguably at
high risk of developing a chronic health condition and
already effectively medicalized [60]. It follows that the
recruitment rates observed in our study may not be trans-
ferrable to studies recruiting people in the general popula-
tion, or in at-risk populations, where the likelihood or
potential impact of a hazard is taken less seriously by
members of that population. Further research may usefully
investigate whether primary prevention trials with better
recruitment rates involve target populations with more se-
vere risk factors.
Although we were testing a specific published hypothe-
sis [5], it is questionable whether those randomized as a
percentage of those screened is the most important statistic
for all researchers to consider. Arguably, the randomization
rate as a function of those eligible has more utility, espe-
cially if the concern is motivation to recruit. In particular,
some prevention trials target individuals who are not
routinely identified by the health system. As a result, the
research team will have to screen larger volumes of people
to establish a pool of eligible study candidates than in a
treatment trial, where the broad diagnosis is already known,
even if eligibility criteria may cause attrition at the margins.
The reader will note from Table 3 that differences in those
randomized as a function of those eligible are not as
marked between prevention and treatment trials as the dif-
ferences observed in this study’s other outcomes. This
observation might undermine any implication, which it is
not clear whether Spilker and Cramer intended, treatment
trials have higher enrollment rates because ‘‘the trial offers
benefit for an active medical problem’’ [5]. However, the
most interesting to us about the hypothesis was not the
question of motivation, but the resource implications that
stem from the necessity to approach and screen larger
numbers of candidates.5. Conclusion
Larger prevention studies are unlikely to randomize as
many of those screened as in a typical treatment trial. Those
planning prevention trials should be aware of other sources
of variation in randomization rates, including the design of
the patient selection pathway and the perceived impact of
the risk factors, which make the target population eligible
for the trial and the value they place on disease prevention.
Future research might seek to replicate this work in other
populations and settings and collect more data on design
and other covariates.Acknowledgments
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